Long-range regulatory interactions at the 4q25 atrial fibrillation risk locus involve PITX2c and ENPEP by Luis A Aguirre et al.
Aguirre et al. BMC Biology  (2015) 13:26 
DOI 10.1186/s12915-015-0138-0RESEARCH ARTICLE Open AccessLong-range regulatory interactions at the 4q25
atrial fibrillation risk locus involve PITX2c and
ENPEP
Luis A Aguirre1, M Eva Alonso1, Claudio Badía-Careaga1, Isabel Rollán1, Cristina Arias1, Ana Fernández-Miñán2,
Elena López-Jiménez1, Amelia Aránega3, José Luis Gómez-Skarmeta2, Diego Franco3 and Miguel Manzanares1*Abstract
Background: Recent genome-wide association studies have uncovered genomic loci that underlie an increased risk
for atrial fibrillation, the major cardiac arrhythmia in humans. The most significant locus is located in a gene desert
at 4q25, approximately 170 kilobases upstream of PITX2, which codes for a transcription factor involved in embryonic
left-right asymmetry and cardiac development. However, how this genomic region functionally and structurally relates
to PITX2 and atrial fibrillation is unknown.
Results: To characterise its function, we tested genomic fragments from 4q25 for transcriptional activity in a mouse
atrial cardiomyocyte cell line and in transgenic mouse embryos, identifying a non-tissue-specific potentiator regulatory
element. Chromosome conformation capture revealed that this region physically interacts with the promoter of
the cardiac specific isoform of Pitx2. Surprisingly, this regulatory region also interacts with the promoter of the next
neighbouring gene, Enpep, which we show to be expressed in regions of the developing mouse heart essential for
cardiac electrical activity.
Conclusions: Our data suggest that de-regulation of both PITX2 and ENPEP could contribute to an increased risk
of atrial fibrillation in carriers of disease-associated variants, and show the challenges that we face in the functional
analysis of genome-wide disease associations.
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Genome-wide association studies (GWAS) have expo-
nentially increased our knowledge of the genetic com-
ponent of human disorders, revealing unsuspected loci
that harbour variants linked to an increased risk of
disease [1]. However, the majority of GWAS signals fall
in non-coding regions of the genome, which has made
their functional analysis particularly challenging [2,3].
Even the identification of the genes targeted by disease-
associated variants is not straightforward, as mere
proximity can result in incorrect identification of the
culprit gene [4].* Correspondence: mmanzanares@cnic.es
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unless otherwise stated.Atrial fibrillation (AF) is the most common cardiac
arrhythmia in humans [5] although its pathophysiologic
basis is still not clearly understood, presenting a challenge
for cardiovascular research and therapy. AF is defined as a
supraventricular tachyarrhythmia characterised by un-
coordinated atrial activation, and is frequently observed
as a consequence of various systemic and cardiac disor-
ders (syndromic AF) [6]. However, in 10% to 20% of cases
AF is not associated with other cardiovascular disease, and
thus is dubbed ‘idiopathic’ or ‘lone’ AF that mostly occurs
in patients under 60. The strong association of AF onset
with risk factors, such as age, sex, ethnicity, hypertension
and other heart diseases [7], originally suggested it being
a non-genetic disorder [8]. Nevertheless, in the last two
decades several epidemiological studies pointed to a sig-
nificant incidence of genetic factors [9]. Furthermore, rare. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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subunits [8], are associated with AF as part of wider
cardiac electrical syndromes.
At least ten loci have been linked to AF by GWAS in
large cohorts of non-related patients of distinct ethnic
backgrounds [10-12]. The most highly AF associated
variants identified in all studies are located on chromo-
some 4q25 [11], 170 kilobases (kb) distal to PITX2 and
within a 1.5 megabases (Mb) intergenic gene desert.
PITX2 encodes an evolutionarily conserved homeodo-
main transcription factor that is involved in the estab-
lishment of left-right asymmetry and cardiovascular
development in the vertebrate embryo. In mice and
humans the PITX2 gene generates several isoforms.
PITX2a and PITX2b are alternative splicing variants
produced from a common promoter, whereas PITX2c is
the product of an alternative promoter and is the main
isoform expressed in the heart [13].
Mouse Pitx2c is first expressed in the left lateral plate
mesoderm of the early embryo, as part of the network
regulating the establishment of left-right asymmetry
during development [14], and is then expressed in the
left side of the heart at early stages [15]. At later stages,
expression follows a dynamic pattern, being present in
the left atrium, the myocardium sleeves of the pulmon-
ary veins, the atrio-ventricular cushions or the base of
the ventricles [16,17]. Germline homozygous deletion of
Pitx2 results in embryonic lethality and numerous
cardiac malformations, such as right atrial isomerism
and outflow tract defects, varying from double outlet
right ventricle or transposition of the great arteries to
persistent truncus arteriosus [18]. More recent research
showed that Pitx2c is expressed in adult mice and human
hearts, predominantly in the left atrium (levels in the right
atrium and the ventricles are 100-fold lower), and that its
levels of expression decrease in atria of AF patients
[13,19]. Furthermore, Pitx2c heterozygous or atrial specific
deletion of Pitx2c display molecular and physiological hall-
marks of human AF [13,19,20], which also is observed
when Pitx2 is deleted in adult mice [21]. Altogether, these
data support the hypothesis that PITX2 could play a causal
role in the pathogenesis of AF and that its function could
be altered by genomic elements located in the vicinity of
the single nucleotide polymorphisms (SNP) in 4q25 that
correlate with of AF.
In this study, we explored whether the 4q25 region
spanning the AF-associated variants identified by GWAS
harbours putative regulatory elements that could be
acting on neighbouring genes. By tissue culture, in vivo
transgenics and analysis of chromatin structure, we have
found that this region contains potentiator cis-regulatory
elements that interact with the promoters of Pitx2c and,
unexpectedly, Enpep, the next gene located downstream
of Pitx2. Given the expression of Enpep in the sinoatrialnode (SAN) and the co-expression of Pitx2 and Enpep
in pro-arrhythmogenic regions of the embryonic heart,
such as the sleeves of the pulmonary veins, our data
suggest that de-regulation of these genes could underlie
increased risk of AF.
Results
Genomic analysis of the 4q25 AF-associated locus
To identify putative cis-regulatory elements located in the
4q25 region we analysed the evolutionary conservation
[22] and distribution of histone modifications associated
with active elements [23] (H3K4me1) in an 85 kb window
containing the main SNPs that have been associated with
an increased risk of AF by GWAS (Figure 1). This window
is centred on the lead rs2200733 SNP [11] that has repeat-
edly been identified as the most significant variant asso-
ciated with AF [10-12,24-26], and spans a region that
includes other distal SNPs (rs2634073 and rs17570669)
that lie in the proximity of sequences highly conserved
between human and mouse (Figure 1A). The region in-
cluding the majority of AF-associated SNPs in 4q25 is
confined to a linkage disequilibrium (LD) block [11],
separated from that containing the coding exons of the
gene and from adjacent LD blocks in the 1.5 Mb gene
desert located centromeric to PITX2 (Figure 1A). It is
also noteworthy that the selected SNPs and the PITX2
gene are contained together in a single topologically as-
sociated domain (TAD; Additional file 1A), as defined
by Hi-C in three different human cell lines [27].
We selected seven genomic fragments (AF1-7) for
further analysis (Figure 1B). Fragments AF1 and AF2 lie
in close proximity to rs2634073 and show high evolu-
tionary conservation. These fragments are included in a
region (hs930) tested as part of a large scale screen for
tissue specific human enhancers by transgenesis in the
mouse embryo [28] and drive reporter expression in the
nervous system and limbs but not in the heart. This
region was also tested in transgenic zebrafish, driving
expression in similar patterns but again not in the devel-
oping heart [29]. AF3 to AF5 are a set of overlapping
fragments that include the lead rs2200733 variant and
other highly associated SNPs, in a region with high con-
servation among placental mammals and H3K4me1
marks of active regulatory elements. Finally, AF6 and
AF7 map to a region conserved in vertebrates including
rs17570669, which has been associated with AF but is
independent of rs2200733 [12].
The 4q25 AF-associated locus contains active regulatory
elements
We tested the regulatory activity of these fragments, cor-
responding to the none-risk haplotype at rs2200733 from
a commercial source of human DNA, by linking them
to a human minimal beta-globin promoter [30] and the
Figure 1 Genomic landscape of the atrial-fibrillation associated region 4q25. (A) A 230 kb view of the 4q25 (hg19; chr4:111,516,448-111,747,857)
gene desert, showing the position of AF risk-associated SNPs (vertical black bars) distal to PITX2. The different PITX2 isoforms of the gene are
shown above with PITX2c, the main cardiac isoform, on top. Below, UCSC tracks of the region showing the distribution of H3K4me1 marks (me1)
in foetal heart (FH), smooth muscle (SM), foetal liver (FL), foetal brain (FB) and human embryonic stem cells (H1); the conservation (cons) between
human and mouse, rat, cow, opossum and chicken; and the linkage disequilibrium structure from the HapMap Project (CEU r2). (B) A 85 kb zoom
of the shaded rectangle shown in A (hg19; chr4:111,662,786-111,747,668) indicating the fragments (AF1-AF7) tested for regulatory activity in this
study. The lead AF risk associated SNP rs2200733 is highlighted in red. AF, atrial fibrillation; UCSC, University of California Santa Cruz genome browser.
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protein (mRFP) [31]. These constructs were transfected
into cultured HL-1 mouse atrial cardiomyocytes [32], a tis-
sue culture model of the physiological conditions in which
PITX2 is active [19]. As a positive control, we used a pre-
viously described enhancer from the Nppa gene (encoding
atrial natriuretic factor; ANF) that recapitulates its en-
dogenous expression in transgenic mice [33]; for negative
controls we used the reporter constructs lacking anygenomic fragment, and containing the pluripotent-specific
Oct4 distal enhancer [34]. Of the seven fragments, only
AF3, which contains rs2200733 (Figure 1B), showed
significant activity compared with negative controls
(Figure 2A). While this could seem surprising given that
other fragments show a more robust signal for histone
modifications associated to regulatory elements (for ex-
ample AF4, Figure 1B), enhancer prediction based on
histone marks is only accurate in a fraction of cases [35].
Figure 2 Regulatory activity of 4q25 genomic elements in cultured HL-1 atrial cardiomyocytes and in transgenic mouse embryos. (A) HL-1 transfection
assays with the 4q25 fragments AF1 to AF7 show that only AF3 exhibits regulatory activity (P = 0.0004) as compared with the positive (NppaPE) and
negative (Oct4DE, bRFP) controls. (B) Transfection assays of AF3.1 to AF3.6 overlapping fragments; only AF3.5 (P = 0.0002) and AF3.6 (P = 0.0006) show
significant activity. Deletion of the overlapping fragment between them, which itself shows strong activity (AF3.5∩3.6; P = 0.00004), abrogates activity of
AF3.5 (AF3.5Δ) but not of AF3.6 (AF3.6Δ; P = 0.02). (C) AF3 drives lacZ reporter expression in E13.5 transgenic mice embryos to different sites, such as
the facial mesenchyme (FM), limb muscles (LM), and the left gonad (LG). (D-F) Activity in embryonic day (E) 10.5 to 11.5 transgenic embryos of AF3.5
(D) and AF3.6 (E, F) is highly variable, driving expression in diverse sites, such as the central nervous system (CNS) or facial mesenchyme (D), limb
muscles (D, F), somites (E), and heart (F). (G) Reporter activity driven by the PITX2 ASE element is preferentially localised to the left side with
weak expression in the cardiac region. (H) The chimeric ASE + AF3.6 construct behaves in a similar way to ASE but with increased cardiac expression.
(I-J) Sections of the embryos shown in G and H, comparing the region of the right ventricle (RV) of ASE (I) and ASE + AF3.6 (K), which shows a broader
domain of reporter expression. Similarly, expression in the atrioventricular canal (AVC) is broader in ASE + AF3.6 (L) compared to ASE (J). For A and B,
data are expressed as mean ± SEM. Statistical significance versus empty pβRFP was calculated by unpaired Student’s t-test. *P <0.05, ***P <0.001. LA, left
atrium. ASE, asymmetric enhancer; SEM, standard error of the mean.
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analysed its function by generating six overlapping
fragments (AF3.1 to AF3.6) of 1 to 2 kb each (Additional
file 1B). When tested in HL-1 cells, only AF3.5 and AF3.6
showed activity (Figure 2B). It is noteworthy that AF3.3,
which contains rs2200733, is not active in this assay.AF3.5 and AF3.6 overlap in 80 base pairs (bp), so we then
tested the activity of this minimal fragment (AF3.5∩3.6) in
HL-1 cells as well as versions of AF3.5 and AF3.6 where
the overlap was removed (AF3.5Δ, AF3.6Δ). AF3.5∩3.6
showed strong activity in HL-1 cells, and while AF3.5Δ
was not active, AF3.6Δ retained activity although at a
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this 80 bp minimal fragment is highly conserved be-
tween human and mouse, and that its sequence corre-
sponds to a short interspersed nuclear element of the
MIR3 family. It has been shown that repeat sequences can
act as enhancers in experimental assays [36], although
their putative function in vivo is still under debate [37].
Therefore, we can conclude that the regulatory activity of
AF3 in this assay is located in AF3.6, and that additional
activity may be present in the overlapping fragment of
AF3.5 and AF3.6.
Next, we assayed the activity of fragments AF3-5 and
AF7 in transgenic mouse embryos, using the lacZ gene
as a reporter. Again, only AF3 showed enhancer activity
(Figure 2C, Additional file 2), confirming the results of
the tissue culture assays. AF3 drives reporter expression
in facial mesenchyme, limb muscles, and the left gonad,
some of which are sites of expression of endogenous
Pitx2 [14,38]. Contrary to expectations, AF3 did not
drive expression in the developing heart. We reasoned
that regulatory elements from PITX2 underlying the
association with AF might not be active during develop-
ment, and instead drive cardiac-specific expression of
PITX2 in the adult. We therefore generated transgenic
mice and examined reporter expression in the heart at
postnatal day 3. Again, we found no expression in
cardiac tissues (Additional file 2).
When tested in mouse transgenic assays, both AF3.5
and AF3.6 showed activity (Figure 2D to F). Sites of
expression include facial mesenchyme, limb muscles,
somites, or pericardium, but we did not observe a repro-
ducible pattern driven by these fragments. We can rule
out the possibility that this heterogeneity is due to non-
specific reporter activation as a consequence of integra-
tion site of the transgene, because of the very low per-
centage of lacZ positive embryos (out of the total
number of transgenics as assessed by genotyping) ob-
tained for genomic fragments tested showing no activity
(0% to 5%) as compared to those that do (20% to 45%;
Additional file 2).We also tested activity in transgenic
embryos of the minimal AF3.5∩3.6 fragment, finding
that it was not active (1 weak lacZ+ embryo out of 17
transgenics; Additional file 2).
The 4q25 regulatory elements show non-specific
potentiator activity
The above results suggest that these 4q25 elements,
while they have regulatory potential, do not confer tissue
specificity. To test this hypothesis further, we transfected
fragments AF3, AF3.5 and AF3.6 into two cell types unre-
lated to the cardiac lineage: the mouse teratocarcinoma-
derived pluripotent cell line P19 and human embryonic
kidney (HEK) cells. We found that all three fragments
were active in both cell types, closely matching the degreeof activation in HL-1 cells (Additional file 3). As expected,
the Oct4-DE was active in P19 but not in HEK cells; in
contrast, the Nppa enhancer was not active in P19 but
showed activity in HEK cells, as expected given the
endogenous expression of NPPA in human kidney [39].
Overall, our results suggest that the regulatory elements
detected in 4q25 do not act as cell type-specific
enhancers, but rather as accessory elements that can
potentiate the activity of tissue-specific enhancers
located elsewhere in the locus.
To further prove the putative potentiator activity of
4q25 elements, we assessed the effect of AF3.6 on the
activity of a previously identified intronic enhancer from
Pitx2, which drives left-sided expression in the embryo
[40]. This asymmetric enhancer (ASE) is evolutionarily
conserved in sequence and function, but it is noteworthy
that the ASE from human PITX2 only drives weak ex-
pression in the mice heart compared with its mouse
homologue [41]. We generated a chimeric construct
containing both human AF3.6 and ASE and compared
its activity to that of ASE alone in transgenic mouse
embryos at 10.5 (Figure 2G-L). We first observed that
when using the chimeric ASE + AF3.6 construct, the
variability associated with AF3.6 alone is lost, and all
embryos show the characteristic left-sided expression
described for the ASE (Figure 2G, H). Importantly, we
found that there is no additive effect of both genomic
fragments as that observed when placing together differ-
ent enhancers in the same transgenic construct [42]. In
fact, we observed that adding AF3.6 to the ASE appar-
ently increased the levels of reporter expression in the
cardiac region (Figure 2G, H), as seen in sections where
domains of reporter activity in the right ventricle and in
the atrio-ventricular canal are expanded in ASE + AF3.6
embryos compared to ASE (Figure 2I-L). When we
examined in detail reporter expression in the developing
heart for all transgenic embryos, we found that AF3.6
increases the number of embryos expressing lacZ in the
left atrium (two out of five for ASE, as compared to
seven out of ten for ASE + AF3.6; Additional file 4). The
results of these assays further suggest that 4q25
elements have an accessory role in defining PITX2
expression acting in conjunction with other regulatory
elements.
The three-dimensional architecture of the Pitx2 locus
identifies promoter-specific long range interactions
Although the above evidence shows that 4q25 includes
regulatory elements, there is no direct evidence that this
genomic region acts on PITX2 or that, if it does, it shows
any specificity regarding the cardiac and non-cardiac iso-
forms produced from two alternative promoters. To an-
swer these questions, we analysed the three-dimensional
organisation of the locus by chromosome conformation
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contact the promoters of PITX2. Because we aimed to per-
form the assays in the physiological context of the heart,
we selected the mouse genome region syntenic to human
4q25 and analysed chromatin from the atria and ventriclesFigure 3 Long-range chromatin interactions in the mouse Pitx2 genomic l
genome syntenic to human 4q25. The approximate locations of regions or
af3, in red, is orthologous to human AF3, which contains the lead SNP rs22
generated are indicated (Pitx2ab, blue; Pitx2c, red; Enpep, green). Genomic H
primers are represented by black horizontal bars (1 to 10; F and R denote prim
frequencies (y-axis), between the test fragments and the promoters of Pitx2ab
graph, the highest crosslinking frequency values were set to 1. Genome coord
significance was assessed following one-way ANOVA test of Student-New
variance; SEM, standard error of the mean; 3C, chromosome conformationof adult mouse hearts. Based on the relative order and
position of conserved sequence blocks between human
and mouse, we could unambiguously map mouse frag-
ments (af1-af7) equivalent to the human AF1-AF7 frag-
ment series tested above (Figure 3A).ocus. (A) Schematic representation of a 300 kb region of the mouse
thologous to human AF1-AF7 are indicated by pink boxes (af1 to af7;
00733). The promoter regions from which anchor primers for 3C were
indIII fragments tested for their interaction with anchor promoter
er design). (B-D) Normalised 3C interactions, expressed as crosslinking
(B), Pitx2c (C) and Enpep (D) in atria (red) and ventricle (blue). In each
inates (x-axis) are from the mouse NCBI37/mm9 assembly. Statistical
man-Keuls. ***P <0.001. Error bars represent ± SEM. ANOVA, analysis of
capture.
Aguirre et al. BMC Biology  (2015) 13:26 Page 7 of 13We probed the interaction of HindIII restriction frag-
ments containing the Pitx2a,b or Pitx2c promoter with
ten fragments spanning over 100 kb of the distal region
on mouse chromosome 3 syntenic to the AF-associated
4q25 locus in humans (Figure 3A). Using atria and ven-
tricles from adult mice we observed a clear pattern of
long range interactions, with regions interacting specific-
ally with the Pitx2a,b promoter (fragment 2R; Figure 3B),
the Pitx2c promoter (fragment 6F; Figure 3C), or with both
(fragment 8F; Figure 3B, C). The latter result prompted us
to ask if fragment 8F had regulatory activity in HL-1 cells,
since it is not included in any of the previously tested
fragments. This was not the case, suggesting that this
genomic region has other architectural roles in config-
uring the regulatory landscape of Pitx2. To further
examine the specificity of chromatin interaction be-
tween the AF-associated region and Pitx2c, we checked
the interaction of a fragment containing the promoter
of Enpep, the next neighbouring gene distal to Pitx2 in
both mouse and humans (Figure 3A). To our surprise,
we found a robust interaction between fragment 6F and
Enpep (Figure 3D), suggesting that the 4q25 regulatory
landscape is partially shared between PITX2 and ENPEP.
The specificity of the interactions of fragments 2R, 6F and
8F with Pitx2ab, Pitx2c and Enpep was tested by using a
series of control primers located upstream and down-
stream of the promoters, which showed no interactions
(Additional file 5).
We next asked if the interactions we observed showed
regional differences in atria, as AF constitutes a disorder
of the left atrium and this is the region where PITX2 is
prominently expressed [13]. While fragment 2R inter-
acted specifically with the Pitx2ab promoter in both left
and right atrium, fragment 6F interacts only in left
atrium with Pitx2c and Enpep. On the other hand, frag-
ment 8F shows interaction with Pitx2c in both atria but
only in the right atrium with Enpep (Figure 4A). Given
the fact that the promoters of Pitx2c and Enpep share
many of the interactions tested, we examined if they
were physically associated and if this was region-specific.
We found a robust and specific promoter-promoter
interaction in both atria and in ventricles (Figure 4B),
therefore independent of transcription and in line with re-
cent observations on the role of pre-existing promoter-
promoter interactions for structuring the genome [45].
It should be noted that fragment 6F contains the
region conserved with human fragment AF3, thereby sug-
gesting that the region with regulatory activity and that
contains the lead SNP associated with AF (rs2200733) in-
teracts in a specific manner with the promoters of the
cardiac-specific isoform of Pitx2 and the neighbouring
gene, Enpep. The 3C analysis of the mouse Pitx2/Enpep
locus thus revealed an unexpected complexity of specific
and shared chromatin interactions between the regionscontaining the potentiator elements and the different pro-
moters studied that could be related to their function.
Enpep is expressed in arrhythmogenic sites in the
embryonic heart
ENPEP encodes aminopeptidase A, which cleaves angio-
tensin II to produce angiotensin III as part of the renin-
angiotensin system [46]. Therefore ENPEP is involved
in the control of blood pressure, and accordingly it is
expressed in the renal system and endothelial cells, and
knockout mice for Enpep develop hypertension [47].
However, at present there is no report for expression or
a role of Enpep in the heart. In light of our results, we
examined the expression of Enpep in the E14.5 mouse
embryos by in situ hybridization on tissue sections
(Figure 5). Enpep is strongly expressed in the endo-
thelial lining of the lungs, but also in a specific and re-
stricted pattern in the developing heart (Figure 5A, D).
We compared Enpep expression with that of Pitx2
(Figure 5B, E) and Hcn4 (Figure 5C, F), which encodes a
voltage-gated ion channel and at this stage is a marker
of most of the cardiac conduction system [48,49]. This
analysis showed that Enpep is co-expressed with Pitx2
in the pulmonary veins but not in the myocardium of
the left atrium (Figure 5A, B, D, E), and is co-expressed
with Hcn4 in the left and right superior venae cavae and
in the SAN (Figure 5A, C, D, F). Enpep is thus expressed
in the embryonic mouse heart in key components of the
cardiac conduction system such as the SAN. Moreover,
Enpep is also expressed at the base of the pulmonary
veins and the junction of the caval veins, regions prone
to initiate ectopic electrical beats, which lead in many
cases to the onset of AF [7].
Discussion
The advent of GWAS has radically changed our pers-
pective on the genetic analysis of common diseases in
humans. On the one hand, a plethora of novel loci
linked to increased disease risk have been uncovered,
which await further analysis before possible translation
to the clinic [2]. On the other hand, the vast majority of
risk variants are located in non-coding genomic se-
quences, pointing to a fundamental role for variation in
cis-regulatory elements as the basis of common diseases
[50,51]. Understanding the role and function of these
genomic elements will be fundamental to making the
most of the discoveries of GWAS.
The genomic analysis of AF is a prime example in this
regard. All GWAS carried out to date have shown that
the major loci for AF lie in an intergenic gene desert in
4q25, located distal to the developmental regulator
PITX2 [10-12]. Despite its early role in establishing the
left-right patterning of the heart and its prominent ex-
pression in the left atrium, no evidence suggested a role
Figure 4 Differential chromatin interactions of Pitx2 and Enpep in left and right atrium. (A) Normalised 3C interactions, expressed as crosslinking
frequencies (y-axis), between fragments 2R, 6F and 8F, and the promoters of Pitx2ab, Pitx2c and Enpep, in left (red) and right (yellow) atrium. (B)
3C interaction between the Pitx2c and Enpep promoters, including control regions upstream (c4) and downstream (c5) of Enpep (see Additional
file 5), in left (red) and right (yellow) atrium, as well as in ventricles (blue). In each graph, the highest crosslinking frequency values were set to 1.
Statistical significance was assessed following one-way ANOVA test of Student-Newman-Keuls. *P <0.05, **P <0.01, ***P <0.001. Error bars represent ±
SEM. ANOVA, analysis of variance; SEM, standard error of the mean; 3C, chromosome conformation capture.
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analysis of loss-of-function mouse models of Pitx2 have
confirmed that it plays a pivotal role in regulating differ-
ent atrial phenotypes by distinguishing electrical from
working myocardium in the right and left atria respect-
ively [13,19,20]. However, no reports to date have provided
evidence as to how distal variants in 4q25 act on PITX2.
Even more surprisingly, a recent report showed that 4q25
variants do not correlate with PITX2 expression in atrial
tissue from human patients [52]. This evidences that vari-
ants identified by GWAS may have extremely subtle ef-
fects, which fall below the threshold of detection of
current analytical tools and approaches.
Our analysis of the regulatory structure of the 4q25
locus shows that genomic sequences in close proximity to
AF-linked variants can act as transcriptional regulatoryelements both in tissue culture and in mouse embryos.
Rather unexpectedly, and contrasting with other cases of
GWAS-related enhancers in the cardiovascular system
[53,54], these elements are not specific to cardiac cell
types, either in culture or in vivo. The 4q25 elements show
equal activity when transfected into cell types of different
origin. Furthermore, in transgenic mouse embryos these
elements drive highly variable patterns of reporter expres-
sion. These results suggest that the cis-regulatory elements
in 4q25 do not act as classical tissue-specific enhancers,
but as potentiator elements that would act in cooperation
with elements located elsewhere in the locus that dictate
tissue restricted expression. In the case of mouse Pitx2, an
intronic enhancer (ASE) has been described that drives
left-side specific expression in the early embryo and later
in the heart, liver and other organs [41]. It is conceivable
Figure 5 Enpep is expressed in the embryonic mouse heart. (A to F) Expression of Enpep (A, D), Pitx2 (B, E) and Hcn4 (C, F) in E14.5 mouse
embryos shown by in situ hybridization on two sets of consecutive sections (A to C and D to F). In addition to strong expression in the endothelial
lining of the lungs, Enpep is expressed in a restricted pattern in the heart (A, D), where it is co-expressed with Pitx2 in the pulmonary veins (PV; zoom
in A and B) and with Hcn4 in the leaflet of the venous valve (VV) and left superior vena cava (LSVC; zoom in A and C) as well as in the right superior
vena cava (RSVC) and sinoatrial node (SAN; zoom in D and F). It is noteworthy that Enpep is not expressed in the myocardium of the left atria (LA), as is
Pitx2 (zoom in B and E). AVN-His, atrial ventricular node-bundle of His; RA, right atria. Scale bars, 1 mm; close-ups, 200 μm. E, embryonic day.
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of PITX2 requires interplay of the ASE and the 4q25
potentiator. In fact, when placed together and tested by
transgenics, the variability of 4q25 elements is lost and it
can modulate the activity of ASE. It is possible that this
potentiator could also modulate the activity of other yet to
be identified regulatory elements from the locus.
By analysing the physical interaction between promoters
and intergenic sequences of the mouse region syntenic to
4q25, we have found a further degree of complexity in the
chromatin structure of the region. First, there is a clear
specificity in the interaction of distal elements with the
alternative promoters of the different Pitx2 isoforms,
despite their being separated by less than 10 kb. In this
regard, it is noteworthy that the region containing the po-
tentiator activity we have described interacts specifically
with the promoter of the cardiac-specific Pitx2c isoform.
Furthermore, this interaction occurs specifically in the left
atrium. These results provide additional support to the
specific role of the region identified by GWAS in regulat-
ing PITX2 in the heart.More surprising was the fact that this same region phys-
ically interacts with the promoter of Enpep, the neighbour-
ing gene located distal to Pitx2. This opens the possibility
that Enpep could also be a transcriptional target of the
identified cis-regulatory elements. ENPEP, as part of the
renin-angiotensin system, has been shown to control blood
pressure, and hypertension is a known risk factor for AF
[55]. However, 4q25 variants are associated with lone AF,
with no co-occurrence of hypertension [25], and independ-
ent variants located in the proximity of ENPEP but not in
the 4q25 AF loci are associated with changes in blood pres-
sure [56]. Furthermore, there is no reported correlation
between expression of ENPEP and 4q25 variants in the
blood or adipose tissue [11]. We can therefore conclude
that the possible regulation of ENPEP by the 4q25 potenti-
ator elements would be unrelated to its known role in the
control of blood pressure. Our re-evaluation of Enpep ex-
pression in the developing mouse heart by in situ
hybridization reveals co-expression with Pitx2 in the pul-
monary veins, a region with pro-arrhythmogenic potential
[57], and in the SAN of the right atria, a key component of
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is generated. Our preliminary observations suggest that in-
correct regulation of ENPEP in these locations could be
linked to AF. The precise role of ENPEP in the heart re-
mains to be identified and could offer novel insight into
the pathogenesis of AF.
Conclusions
We have shown that novel cis-regulatory elements are
located in the region of 4q25 associated with an in-
creased risk for AF. These elements establish complex
long-distance interactions with the promoters of both
Pitx2c and Enpep, and therefore could regulate the tran-
scription of these genes. A potential limitation of our
study is the fact that while we have used human gen-
omic DNA for regulatory assays, the chromatin struc-
ture of the Pitx2/Enpep locus and the expression of
Enpep in the heart was carried out in mouse. However,
the sequence conservation in the regions studied, as well
as conserved synteny of the locus and of gene functions
strongly suggests that regulatory mechanisms will also
be conserved between human and mouse. Overall, our
results suggest that de-regulation of either one or both
PITX2 and ENPEP might have a causal role in the devel-
opment of AF. Future work will be needed to identify the
causal variants and the upstream regulatory factors that
act through the potentiator elements described here.
Our study also highlights the challenges we face in the
functional analysis of genetic variation identified by
GWAS. Our understanding of the nature and function
of non-coding genomic elements is still incomplete, des-
pite the wealth of genome-wide data available through
ENCODE and similar projects [58,59]. We are greatly
limited by the breadth and specificity of available assays
to interrogate the function of a DNA fragment. We can
hypothesise that only a fraction of GWAS hits will rep-
resent classical tissue-specific enhancers, whose charac-
terisation is feasible with current tools. Many cases will
affect other regulatory elements with not such a clear-cut
and easily identifiable role in gene transcription, such as
potentiators or modulators (as we have identified here),
but also silencers, insulators or stabilisers. Novel tools and
assays will need to be devised to fully understand the regu-
latory variation underlying common human disease.
Methods
Cloning
Commercial Clontech (Mountain View, California, USA)
human DNA was used for PCR amplification of all the
tested genome fragments from chromosome 4q25
(for primers used see Additional file 6). We used the
pGem-T Easy Promega (Madison, Wisconsin, USA) vec-
tor for initial cloning of the PCR products, followed by
digestion with NotI New England BioLabs (Ipswich,Massachusetts, USA) and subsequent cloning in
enhancer-detection vectors containing the human min-
imal beta-globin promoter and either monomeric red
fluorescence protein (pβRFP) or lacZ (p1230) reporter
genes.
Cell culture and transfections
Mouse HL-1 atrial cardiomyocytes were cultured in
Claycomb medium Sigma (St. Louis, Missouri, USA)
supplemented with 10% (v/v) inactive (56°C, 30 mi-
nutes) fetal bovine serum (FBS) (Sigma), 4 mmol/L L-
glutamine (Sigma), 100 μmol/L norepinephrine (Sigma)
and 100 U/mL penicillin-streptomycin (Sigma). All
seeding supports were previously coated for 24 hours
with a solution of gelatin (0.02% w/v, Sigma) and fibro-
nectin (25 μg/mL, Sigma). Mouse P19 embryonic terato-
carcinoma cells (a kind gift from Christine Mummery,
Leiden University Medical Center, The Netherlands)
were cultivated in α-minimal essential medium (α-
MEM, Gibco (Grand Island, New York, USA)) contain-
ing 10% FBS, 100 U/mL penicillin-streptomycin and 4
mmol/L L-glutamine. HEK293T human embryonic kid-
ney cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Sigma) supplemented with 10% FBS,
4 mmol/L L-glutamine and 100 U/mL penicillin-
streptomycin.
One day before transfections, cells were counted and
plated at a density of 5 × 105 cells per p12 well (HL-1
cells) or p6 (P19 and HEK293T) with complete growth
medium and no antibiotics. Cells were co-transfected
with 2 μg of pβRFP vector containing the appropriate
4q25 fragment and 1 μg of pCAGGS-GFP (a kind gift
from Joaquín Rodríguez-León, University of Extremadura,
Badajoz, Spain) as an internal transfection efficiency
control; co-transfections were performed with 6 μL of
Lipofectamine 2000 Invitrogen (Waltham, Massachusetts,
USA). Cells were transferred to complete medium with
antibiotics after five hours. The empty vector pβRFP was
used as a negative control.
Forty-eight hours after transfection, cultures were
photographed (Zeiss) and fluorescent cells automatically
counted (ImageJ) in twelve independent random fields
per well (for the transfections of AF1 to AF7 in HL-1
cells; Figure 2A), or were measured by fluorescence acti-
vated cell sorting (FACS) (LSRFortessa (BD Biosciences;
Franklin Lakes, New Jersey, USA) Flow Cytometer) in all
other transfections. Three independent experiments with
three technical replicates each were quantified in all
cases. Relative regulatory enhancer activity was then cal-
culated as the ratio of red cells (RFP+) to total green
(GFP+) control cells, expressed as mean ± standard error
of the mean (SEM) and statistically analysed by unpaired
Student’s t-test (Prism5), with the significance threshold
set at P <0.05.
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p1230-derived constructs were digested with SacII and
SalI (New England BioLabs) to remove the plasmid
backbone, and the fragment was purified using the
Qiagen gel extraction kit. DNA fragments were diluted
in microinjection buffer (10 mmol/L Tris–HCl, pH7.4,
0.1 mmol/L ethylenediaminetetraacetic acid (EDTA))
at 5 to 7 ng/μL and injected into zygote pronuclei ob-
tained from crosses of (C57BL/6xCBA/J)F1 mice. Injected
zygotes were transferred to CD1 foster mothers, following
standard procedures [60]. At the desired stage, mice were
euthanised and embryos dissected and stained for β-
galactosidase activity [60]. All embryos were genotyped for
lacZ by PCR, using primers for Myogenin (Additional
file 6) as an internal control for calculating transgenic
efficiency and the percentage of embryos expressing
lacZ (Additional file 2).
Animal studies were approved by the local ethics com-
mittee. All animal procedures conformed to EU Directive
2010/63EU and Recommendation 2007/526/EC regarding
the protection of animals used for experimental and other
scientific purposes, enforced in Spanish law under Real
Decreto 1201/2005.
Chromosome conformation capture (3C) assays
The 3C protocol was performed essentially as described
[61]. Hearts from adult (C57BL/6xCBA/J)F1 female mice
were dissected into atria and ventricles. After mincing
with a scalpel, tissue was mechanically disrupted in 10
volumes of cold PBS, centrifuged at 3,000 g, and the
cell supernatants cross-linked with 2% formaldehyde for
eight minutes at room temperature. Nuclei were ex-
tracted with nuclear extraction buffer and the chromatin
was digested with HindIII on a shaking platform at 37°C
overnight. The cross-linked and digested chromatin
products were ligated with T4 ligase (100 Weiss units) at
15°C for 12 hours in 7 mL 1 × ligation buffer. Sample
quality was measured by semi-qPCR of the XPB/Eccr3
locus, as a control of non-tissue-specific chromatin con-
formation (see Additional file 6 for primer sequences).
Only samples with more than 70% amplification effi-
ciency were used as experimental templates. BAC clones
(20 μg) containing XPB/Eccr3 (MRC Geneservice, clone
344-C18), Pitx2 (CHORI, clone RP24-215O15), Enpep
(CHORI, clone RP24-172B1) and 3:G3 tested region
(CHORI, clone RP23-356C23) were treated in parallel,
to generate the control templates.
All primers used (Additional file 6) were designed in
an approximately 300 kb region of mouse 3:G3 chromo-
some spanning the syntenic human 4q25 locus in which
the GWAS-identified AF-related variants, PITX2 and
ENPEP genes are located. Anchor primers were designed
within the Pitx2ab, Pitx2c and Enpep promoter se-
quences (Figure 3). Three technical replicates of threeindependent experiments were performed for all sets of
test-anchor primers for each tissue. Physical interactions
among anchor and test primers, in the experimental and
control templates, were measured by qPCR (SYBR® Green)
and resulting frequencies were calculated and normalised
using the XPB/Eccr3 locus as control [61,62]. Statistical
analysis, assuming a normal distribution of data, was per-
formed by one-way analysis of variance (ANOVA) test of
Student-Newman-Keuls of the significance of differences
among biological samples; the significance threshold was
set at P <0.05. Error bars represent the SEM for the three
biological replicates.
In situ hybridization
In situ hybridization was performed on sections of E14.5
embryos essentially as previously described [63]. A pan-
Pitx2 probe was kindly provided by José Luis de la Pompa
(CNIC, Madrid, Spain). While this probe recognises all
Pitx2 isoforms, only Pitx2c is expressed in the heart [64].
Hcn4 and Enpep dsDNA were amplified by PCR from
C57Bl/6 J DNA with primers containing T7 or SP6 RNA
polymerase initiation sites (Additional file 6). Sense and
anti-sense RNA probes were prepared by PCR using
digoxigenin-labelled dsDNA as template Roche (Basel,
Switzerland); sense probes were used as negative controls.
Embryos used for different probes were processed in par-
allel in all assays.Additional files
Additional file 1: Genomic analysis of 4q25. (A) TAD structure of the
4q25 genomic region (hg19; chr4:110,940,551-113,100,551). Hi-C analysis
in three different human cell lines (IMR90, lung fibroblasts; hES, embryonic
stem cells; GM12878, lymphoblastoid cells) identifies stable TADs in the gene
desert surrounding PITX2, one of which includes both the gene promoter
and the AF-associated SNPs (highlighted in green). Hi-C data were obtained
from http://yuelab.org/hi-c/ [27] (B) Overlapping fragments from AF3.
Detailed view of the genomic landscape and evolutionary conservation
of the region surrounding fragment AF3 and of the sub-fragments
(AF3.1 to AF3.6) used in this study (hg19; chr4:111,706,648-111,715,384).
Legend as in Figure 1.
Additional file 2: Results of transgenic experiments.
Additional file 3: 4q25 regulatory elements do not show cell-type
specificity. Activity of 4q25 regulatory elements (AF3, AF3.5 and AF3.6)
in mouse HL-1 cardiomyocytes (dark grey), compared to mouse P19
teratocarcinoma (light grey) and human HEK293T embryonic kidney
(black) cells. Nppa proximal (NppaPE) and Oct4 distal (Oct4DE) enhancers
were used as controls of cell type specificity and the empty pβRFP as a
control of basal activity. Data are expressed as mean ± SEM. Statistical
significance versus empty pβRFP was calculated with the unpaired Student’s
t-test. *P <0.05, **P <0.01 and ***P <0.001.
Additional file 4: Assessment of reporter activity in ASE and
ASE+AF3.6 transgenic embryos.
Additional file 5: Specificity of 3C interactions with Pitx2 and Enpep
promoters. (A) Schematic representation of the interacting regions
(2R, 6F and 8F; Figure 3) and of the Pitx2 and Enpep genes showing the
location of promoter specific anchor primers (Pitx2ab, Pitx2c, Enpep) and
control anchor primers located upstream of Pitx2ab (c1), in between
Pitx2ab and Pitx2c (c2), downstream of Pitx2c (c3), and upstream (c4) or
Aguirre et al. BMC Biology  (2015) 13:26 Page 12 of 13downstream (c5) of Enpep. (B-D) Normalised 3C interactions, expressed as
relative crosslinking frequencies (y-axis), between 2R (B), 6F (C) and 8F (D)
fragments and controls (c1-c5) and promoters (Pitx2ab, Pitx2c and
Enpep), in atria (red) and ventricles (blue). In each graph, the highest
crosslinking frequency values were set to 1. Statistical significance was
assessed following one-way ANOVA test of Student-Newman-Keuls.
**P <0.01, ***P <0.001. Error bars represent ± SEM.
Additional file 6: Primers used in this study.
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